122 related articles for article (PubMed ID: 25154878)
1. Repositioning the substrate activity screening (SAS) approach as a fragment-based method for identification of weak binders.
Gladysz R; Cleenewerck M; Joossens J; Lambeir AM; Augustyns K; Van der Veken P
Chembiochem; 2014 Oct; 15(15):2238-47. PubMed ID: 25154878
[TBL] [Abstract][Full Text] [Related]
2. Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.
Gladysz R; Adriaenssens Y; De Winter H; Joossens J; Lambeir AM; Augustyns K; Van der Veken P
J Med Chem; 2015 Dec; 58(23):9238-57. PubMed ID: 26575094
[TBL] [Abstract][Full Text] [Related]
3. Substrate Activity Screening (SAS) and Related Approaches in Medicinal Chemistry.
Gladysz R; Lambeir AM; Joossens J; Augustyns K; Van der Veken P
ChemMedChem; 2016 Mar; 11(5):467-76. PubMed ID: 26845065
[TBL] [Abstract][Full Text] [Related]
4. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors.
Wyss DF; Wang YS; Eaton HL; Strickland C; Voigt JH; Zhu Z; Stamford AW
Top Curr Chem; 2012; 317():83-114. PubMed ID: 21647837
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1.
Zhao G; Yuan C; Wind T; Huang Z; Andreasen PA; Huang M
J Struct Biol; 2007 Oct; 160(1):1-10. PubMed ID: 17692534
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of non-basic inhibitors of urokinase-type plasminogen activator (uPA).
Venkatraj M; Messagie J; Joossens J; Lambeir AM; Haemers A; Van der Veken P; Augustyns K
Bioorg Med Chem; 2012 Feb; 20(4):1557-68. PubMed ID: 22285569
[TBL] [Abstract][Full Text] [Related]
7. Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator.
Frederickson M; Callaghan O; Chessari G; Congreve M; Cowan SR; Matthews JE; McMenamin R; Smith DM; Vinković M; Wallis NG
J Med Chem; 2008 Jan; 51(2):183-6. PubMed ID: 18163548
[TBL] [Abstract][Full Text] [Related]
8. Fragment-based drug design.
Feyfant E; Cross JB; Paris K; Tsao DH
Methods Mol Biol; 2011; 685():241-52. PubMed ID: 20981527
[TBL] [Abstract][Full Text] [Related]
9. Efficient search of chemical space: navigating from fragments to structurally diverse chemotypes.
Wassermann AM; Kutchukian PS; Lounkine E; Luethi T; Hamon J; Bocker MT; Malik HA; Cowan-Jacob SW; Glick M
J Med Chem; 2013 Nov; 56(21):8879-91. PubMed ID: 24117015
[TBL] [Abstract][Full Text] [Related]
10. Discovering novel ligands for macromolecules using X-ray crystallographic screening.
Nienaber VL; Richardson PL; Klighofer V; Bouska JJ; Giranda VL; Greer J
Nat Biotechnol; 2000 Oct; 18(10):1105-8. PubMed ID: 11017052
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations.
Zhu K; Jiang C; Tao H; Liu J; Zhang H; Luo C
Bioorg Med Chem Lett; 2018 May; 28(9):1476-1483. PubMed ID: 29628326
[TBL] [Abstract][Full Text] [Related]
12. Identification of B. anthracis N(5)-carboxyaminoimidazole ribonucleotide mutase (PurE) active site binding compounds via fragment library screening.
Lei H; Jones C; Zhu T; Patel K; Wolf NM; Fung LW; Lee H; Johnson ME
Bioorg Med Chem; 2016 Feb; 24(4):596-605. PubMed ID: 26740153
[TBL] [Abstract][Full Text] [Related]
13. Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA).
West CW; Adler M; Arnaiz D; Chen D; Chu K; Gualtieri G; Ho E; Huwe C; Light D; Phillips G; Pulk R; Sukovich D; Whitlow M; Yuan S; Bryant J
Bioorg Med Chem Lett; 2009 Oct; 19(19):5712-5. PubMed ID: 19703768
[TBL] [Abstract][Full Text] [Related]
14. Hsp90 inhibitors and drugs from fragment and virtual screening.
Roughley S; Wright L; Brough P; Massey A; Hubbard RE
Top Curr Chem; 2012; 317():61-82. PubMed ID: 21647838
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery.
Erlanson DA; Arndt JW; Cancilla MT; Cao K; Elling RA; English N; Friedman J; Hansen SK; Hession C; Joseph I; Kumaravel G; Lee WC; Lind KE; McDowell RS; Miatkowski K; Nguyen C; Nguyen TB; Park S; Pathan N; Penny DM; Romanowski MJ; Scott D; Silvian L; Simmons RL; Tangonan BT; Yang W; Sun L
Bioorg Med Chem Lett; 2011 May; 21(10):3078-83. PubMed ID: 21459573
[TBL] [Abstract][Full Text] [Related]
16. Is inhibition process better described with MD(QM/MM) simulations? The case of urokinase type plasminogen activator inhibitors.
Barbault F; Maurel F
J Comput Chem; 2012 Mar; 33(6):607-16. PubMed ID: 22241532
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA).
Matthews H; Ranson M; Tyndall JD; Kelso MJ
Bioorg Med Chem Lett; 2011 Nov; 21(22):6760-6. PubMed ID: 21978672
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Jankun J; Skrzypczak-Jankun E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel inhibitors of DNA methylation by screening of a chemical library.
Ceccaldi A; Rajavelu A; Ragozin S; Sénamaud-Beaufort C; Bashtrykov P; Testa N; Dali-Ali H; Maulay-Bailly C; Amand S; Guianvarc'h D; Jeltsch A; Arimondo PB
ACS Chem Biol; 2013 Mar; 8(3):543-8. PubMed ID: 23294304
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel antimycobacterial chemical agents through the in silico multi-conformational structure-based drug screening of a large-scale chemical library.
Koseki Y; Kinjo T; Kobayashi M; Aoki S
Eur J Med Chem; 2013 Feb; 60():333-9. PubMed ID: 23314046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
